Little-known drugs are now contributing to the US overdose epidemic; the Government Accountability Office finds HHS is at "High Risk Alert"; Moderna begins HIV vaccine trial.
Two little-known drugs, para-fluorofentanyl and metonitazene, are contributing to the nation’s overdose crisis, as they are being seen more often by medical examiners looking into the deaths, a new government report found. According to The Associated Press, these drugs are usually taken with or mixed in with fentanyl, one of the main contributors of the over 100,000 overdose deaths reported in the United States in 2021. However, the drugs are also more powerful than fentanyl and are increasingly the sole reason for some deaths. Naloxone can still work in cases where the 2 drugs are ingested, but more may be needed per case.
A new Government Accountability Office (GAO) report found HHS has failed to fix problems in its pandemic response, threatening the agency’s efficacy in responding to future crises, Politico reports. HHS is now on what the GAO deems “High Risk Alert,” meaning it is susceptible to mismanagement and abuse in the absence of significant changes. An additional 3 dozen agencies are also deemed at high risk. Among the failures outlined are leadership shortcomings, difficulties in collecting and analyzing data, and problems communicating with the public. In Congress, members are calling for the implementation of new guardrails for future emergencies handled by HHS.
Moderna has initiated its trial of an HIV vaccine that uses mRNA technology, ABC News reports. The first participants received doses of the vaccine on January 27, and the trial is in partnership with the International AIDS Vaccine Initiative. Approximately 38 million individuals around the world are currently living with HIV, including 1.3 million in the United States. Throughout the height of the US AIDS epidemic, around 50,000 deaths occurred each year while today, advances in treatment allow patients to manage the virus to the point where viral loads can become undetectable, preventing transmission.
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Technology Takes Center Stage at the 2025 AAD Annual Meeting
March 14th 2025The role of artificial intelligence, DataDerm, and telehealth in advancing dermatology care was discussed throughout the meeting, with experts highlighting their potential regarding patient access and health equity.
Read More
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More